Redeye returns with a more in-depth take on the Q3 results. We make no estimate revisions and reiterate our fair value range. For the share to regain investor interest and confidence, we argue that the coming quarterly reports must continue to deliver in line with, or above, market expectations. We believe the strategic shift can positively impact short- and medium-term sales of OPRA in the US, but we emphasise its early stage.